EyePoint Inc Share Price Today: Live Updates & Key Insights

EyePoint Inc share price today is $13.24, up -4.06%. The stock opened at $13.61 against the previous close of $13.79, with an intraday high of $13.82 and low of $13.115.

EyePoint Inc Share Price Chart

EyePoint Inc

us-stock
To Invest in {{usstockname}}
us-stock

EyePoint Inc Share Price Performance

$13.24 -0.0406(-4.06%) EYPT at 23 Mar 2026 12:58 PM Biotechnology
Lowest Today 13.115
Highest Today 13.82
Today’s Open 13.61
Prev. Close 13.79
52 Week High 19.11
52 Week Low 3.91
Day’s Range: Low 13.115 High 13.82
52-Week Range: Low 3.91 High 19.11
1 day return -
1 Week return -1.78
1 month return -22.62
3 month return -29.99
6 month return -1.12
1 year return +108.53
3 year return +452.3
5 year return +21.1
10 year return -

EyePoint Inc Institutional Holdings

Cormorant Asset Management, LLC 9.98

Suvretta Capital Management, LLC 9.38

BlackRock Inc 5.95

Vanguard Group Inc 5.78

Adage Capital Partners Gp LLC 5.63

Federated Hermes Inc 5.29

Franklin Resources Inc 5.00

Paradigm Biocapital Advisors LP 4.42

TCG Crossover Management, LLC 4.28

Federated Hermes Kaufmann Growth 3.32

Federated Hermes Kaufmann R 3.32

Vanguard Total Stock Mkt Idx Inv 3.12

Orbimed Advisors, LLC 2.96

Franklin Biotechnology Discv A(acc)USD 2.63

Federated Hermes Kaufmann Small Cap A 2.38

Federated Hermes Kaufmann Small Cap Grow 2.38

Geode Capital Management, LLC 2.28

iShares Russell 2000 ETF 2.20

Aberdeen Group PLC 1.92

The Goldman Sachs Group Inc 1.82

State Street Corp 1.77

Franklin Small Cap Growth Adv 1.54

Franklin US Small Cap Growth Equity 1.54

Franklin Biotechnology Discovery A 1.52

abrdn Healthcare Investors 1.45

Parkman Healthcare Partners LLC 1.30

Essex Woodlands Health Ventures 1.30

5AM Venture Management, LLC 1.26

Bank of America Corp 1.21

Spruce Street Capital LP 1.18

Morgan Stanley - Brokerage Accounts 1.17

Biotech Growth Ord 1.06

Vanguard Institutional Extnd Mkt Idx Tr 1.01

Fidelity Small Cap Index 0.89

HSBC GIF Glb Eq Sust Hlthcare AC USD 0.84

Candriam Eqs L Biotech C USD Cap 0.81

iShares Russell 2000 Value ETF 0.78

abrdn Life Sciences Investors 0.73

Federated Hermes MDT SCC Institutional 0.55

Federated Hermes MDT Small Cap Core IS 0.55

EyePoint Inc Market Status

Strong Buy: 9

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

EyePoint Inc Fundamentals

Market Cap 1103.80 M

PB Ratio 3.6031

PE Ratio 0.0

Enterprise Value 817.66 M

Total Assets 364.00 M

Volume 1034795

EyePoint Inc Company Financials

Annual Revenue FY23:42523000 42.5M, FY22:41404000 41.4M, FY21:36939000 36.9M, FY20:34437000 34.4M, FY19:20365000 20.4M

Annual Profit FY23:35479000 35.5M, FY22:33078000 33.1M, FY21:28762000 28.8M, FY20:28613000 28.6M, FY19:17678000 17.7M

Annual Net worth FY23:-100148000 -100.1M, FY22:-124512000 -124.5M, FY21:-63915000 -63.9M, FY20:-52651000 -52.7M, FY19:-62969000 -63.0M

Quarterly Revenue Q3/2025:966000 1.0M, Q2/2025:5333000 5.3M, Q1/2025:24453000 24.5M, Q3/2024:10524000 10.5M, Q2/2024:9477000 9.5M

Quarterly Profit Q3/2025:245000 0.2M, Q2/2025:5168000 5.2M, Q1/2025:23648000 23.6M, Q3/2024:9788000 9.8M, Q2/2024:8076000 8.1M

Quarterly Net worth Q3/2025:-59732000 -59.7M, Q2/2025:-59426000 -59.4M, Q1/2025:-45195000 -45.2M, Q3/2024:-29361000 -29.4M, Q2/2024:-30826000 -30.8M

About EyePoint Inc & investment objective

Company Information EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 214

Industry Biotechnology

CEO Dr. Jay S. Duker M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

EyePoint Inc FAQs

What is the share price of EyePoint Inc today?

The current share price of EyePoint Inc is $13.24.

Can I buy EyePoint Inc shares in India?

Yes, Indian investors can buy EyePoint Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy EyePoint Inc shares in India?

You can easily invest in EyePoint Inc shares from India by:

Can I buy fractional shares of EyePoint Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of EyePoint Inc?

EyePoint Inc has a market cap of $1103.80 M.

In which sector does EyePoint Inc belong?

EyePoint Inc operates in the Biotechnology sector.

What documents are required to invest in EyePoint Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of EyePoint Inc?

The PE ratio of EyePoint Inc is N/A and the PB ratio is 3.60.